199 related articles for article (PubMed ID: 31104228)
1. Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization.
McEneny-King A; Chelle P; Foster G; Keepanasseril A; Iorio A; Edginton AN
J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):411-426. PubMed ID: 31104228
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients.
Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Ferrada A; Monte-Boquet E; Pérez-Alenda S; Bosch P; Querol-Giner F; Poveda JL
Thromb Res; 2021 Sep; 205():99-105. PubMed ID: 34293540
[TBL] [Abstract][Full Text] [Related]
3. Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients.
Chelle P; Yeung CHT; Bonanad S; Morales Muñoz JC; Ozelo MC; Megías Vericat JE; Iorio A; Spears J; Mir R; Edginton A
J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):427-438. PubMed ID: 31115857
[TBL] [Abstract][Full Text] [Related]
4. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.
Hazendonk H; Fijnvandraat K; Lock J; Driessens M; van der Meer F; Meijer K; Kruip M; Gorkom BL; Peters M; de Wildt S; Leebeek F; Cnossen M; Mathôt R;
Haematologica; 2016 Oct; 101(10):1159-1169. PubMed ID: 27390359
[TBL] [Abstract][Full Text] [Related]
5. Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A.
Delavenne X; Dargaud Y; Ollier E; Négrier C
Br J Clin Pharmacol; 2019 Apr; 85(4):771-781. PubMed ID: 30633808
[TBL] [Abstract][Full Text] [Related]
6. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
[TBL] [Abstract][Full Text] [Related]
7. Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach.
Solms A; Iorio A; Ahsman MJ; Vis P; Shah A; Berntorp E; Garmann D
Clin Pharmacokinet; 2020 May; 59(5):605-616. PubMed ID: 31749076
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate
Chelle P; Yeung CHT; Croteau SE; Lissick J; Balasa V; Ashburner C; Park YS; Bonanad S; Megías-Vericat JE; Nagao A; Wynn T; Corrales-Medina F; Tran H; Sharathkumar A; Chitlur M; Sarmiento S; Edginton A; Iorio A
Clin Pharmacokinet; 2020 Feb; 59(2):245-256. PubMed ID: 31435896
[TBL] [Abstract][Full Text] [Related]
9. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
Yu JK; Iorio A; Edginton AN
Thromb Res; 2020 Dec; 196():550-558. PubMed ID: 33157394
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A.
Castaman G; Linari S
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):143-151. PubMed ID: 29257899
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
Björkman S; Blanchette VS; Fischer K; Oh M; Spotts G; Schroth P; Fritsch S; Patrone L; Ewenstein BM; ; Collins PW
J Thromb Haemost; 2010 Apr; 8(4):730-6. PubMed ID: 20398185
[TBL] [Abstract][Full Text] [Related]
12. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
[TBL] [Abstract][Full Text] [Related]
13. Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII.
Abrantes JA; Solms A; Garmann D; Nielsen EI; Jönsson S; Karlsson MO
CPT Pharmacometrics Syst Pharmacol; 2019 Dec; 8(12):894-903. PubMed ID: 31668021
[TBL] [Abstract][Full Text] [Related]
14. Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT
Mingot-Castellano ME; Parra R; Núñez R; Martorell M
Haemophilia; 2018 Sep; 24(5):e338-e343. PubMed ID: 30028549
[TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project.
Hajducek DM; Chelle P; Hermans C; Iorio A; McEneny-King A; Yu J; Edginton A
Haemophilia; 2020 May; 26(3):384-400. PubMed ID: 32281726
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.
Björkman S; Folkesson A; Jönsson S
Eur J Clin Pharmacol; 2009 Oct; 65(10):989-98. PubMed ID: 19557401
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
Björkman S
Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
[TBL] [Abstract][Full Text] [Related]
18. A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients.
Yu JK; Iorio A; Chelle P; Edginton AN
Thromb Res; 2019 Dec; 184():31-37. PubMed ID: 31689604
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing.
Nagao A; Yeung CHT; Germini F; Suzuki T
Thromb Res; 2019 Jan; 173():79-84. PubMed ID: 30496937
[TBL] [Abstract][Full Text] [Related]
20. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.
Cheng X; Li P; Chen Z; Zhang N; Zhen Y; Zhao L; Wang X; Wu R
Haemophilia; 2018 Jan; 24(1):120-125. PubMed ID: 29194866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
